Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARYA Sciences Acquisition Corp VARYE · Entity 137308 | Director | July 12, 2021 | July 12, 2021 |
| BridgeBio Oncology Therapeutics, Inc.BBOT · Entity 5215 | Director | June 16, 2026 | June 18, 2026 |
| Cerevel Therapeutics Holdings, Inc.ARYB · Entity 15182 | Director | June 04, 2020 | June 04, 2020 |
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | Director | February 12, 2026 | February 18, 2026 |
| Immunovant, Inc.IMVT · Entity 3632 | Director | April 07, 2026 | April 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARYA Sciences Acquisition Corp V
Report date July 12, 2021 · Filed July 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-07-12 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-257335) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-257335) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
BridgeBio Oncology Therapeutics, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.73 · Expires 2036-06-15 | Direct | 31,675 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 31,675 · Balance 31,675 F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
Cerevel Therapeutics Holdings, Inc.
Report date June 04, 2020 · Filed June 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-06-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-238488) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-238488) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Enliven Therapeutics, Inc.
Report date February 12, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.16 · Expires 2036-02-12 | Direct | 17,126 |
Reported balance
After 2026-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-12 · Grant · Acquired 17,126 · Balance 17,126 F1: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.
Immunovant, Inc.
Report date April 07, 2026 · Filed April 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,896 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Grant · Acquired 13,880 · Balance 38,896 F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.61 · Expires 2036-04-07 | Direct | 7,061 |
Reported balance
After 2026-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-07 · Grant · Acquired 7,061 · Balance 7,061 F2: These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
F2: These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MyoKardia, Inc.
Report date November 17, 2020 · Filed November 19, 2020
Section 16 reporting ended · disclosed 2020-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 1
1 source rowRow 1 · 2020-11-17 · Other · Disposed 90,209 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. F3: Includes 134 Shares acquired under the Issuer's Employee Stock Purchase Plan on October 31, 2020 in a transaction exempt under Rule 16b-3. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.51 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-17 · Disposition to issuer · Disposed 16,530 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-17 · Disposition to issuer · Disposed 8,748 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.25 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-17 · Disposition to issuer · Disposed 35,150 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.11 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-17 · Disposition to issuer · Disposed 57,400 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.00 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-17 · Disposition to issuer · Disposed 34,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.40 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-17 · Disposition to issuer · Disposed 45,193 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.
F3: Includes 134 Shares acquired under the Issuer's Employee Stock Purchase Plan on October 31, 2020 in a transaction exempt under Rule 16b-3.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2018 Filed Nov 6, 2018 19:30 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantCommon Stock | 272 | $42.16 | $11,467.52 |
DisclosureSEC source: 0000899243-18-028347 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,878 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 16:17 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0000899243-18-020579 · doc4.xml · derivative · entry 4 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The shares subject to this option vest and become exercisable in in two annual installments after July 20, 2017, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 16:17 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 3,101 | $57.28 | $177,625.28 |
DisclosureSEC source: 0000899243-18-020579 · doc4.xml · nonDerivative · entry 3 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,606 F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $57.00 to $57.60 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 16:17 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 4,399 | $56.59 | $248,939.41 |
DisclosureSEC source: 0000899243-18-020579 · doc4.xml · nonDerivative · entry 2 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,707 F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $56.00 to $56.95 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 16:17 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 7,500 | $13.90 | $104,250.00 |
DisclosureSEC source: 0000899243-18-020579 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F1 · price: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:43 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 1,519 | $48.95 | $74,355.05 |
DisclosureSEC source: 0000899243-18-011663 · doc4.xml · nonDerivative · entry 2 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,606 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 30, 2018 Filed May 7, 2018 17:43 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantCommon Stock | 348 | $33.15 | $11,536.20 |
DisclosureSEC source: 0000899243-18-011663 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,125 F1 · kind: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
| April 11, 2018 Filed Apr 12, 2018 20:32 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0000899243-18-010091 · doc4.xml · derivative · entry 3 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,850 Underlying: Common Stock · 5,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments from January 1, 2017, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| April 11, 2018 Filed Apr 12, 2018 20:32 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 5,000 | $50.00 | $250,000.00 |
DisclosureSEC source: 0000899243-18-010091 · doc4.xml · nonDerivative · entry 2 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,777 F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 11, 2018 Filed Apr 12, 2018 20:32 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 5,000 | $12.25 | $61,250.00 |
DisclosureSEC source: 0000899243-18-010091 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 16:08 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 164 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0000899243-18-008700 · doc4.xml · derivative · entry 3 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,748 Underlying: Common Stock · 164 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments with the first installment on February 1, 2016, such that this option is fully exercisable on January 1, 2020. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 16:08 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 164 | $50.95 | $8,355.80 |
DisclosureSEC source: 0000899243-18-008700 · doc4.xml · nonDerivative · entry 2 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,777 F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 16:08 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 164 | $9.08 | $1,489.12 |
DisclosureSEC source: 0000899243-18-008700 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 19:34 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,102 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0000899243-18-005874 · doc4.xml · derivative · entry 3 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,912 Underlying: Common Stock · 5,102 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments with the first installment on February 1, 2016, such that this option is fully exercisable on January 1, 2020. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 19:34 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 5,102 | $60.00 | $306,120.00 |
DisclosureSEC source: 0000899243-18-005874 · doc4.xml · nonDerivative · entry 2 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,777 F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 19:34 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 5,102 | $9.08 | $46,326.16 |
DisclosureSEC source: 0000899243-18-005874 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 19:57 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantRestricted Stock Units · Derivative | 5,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001383 · doc4.xml · derivative · entry 2 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common Stock · 5,700 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 19:57 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $52.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001383 · doc4.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2028-01-15 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2018, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 16:45 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 5,000 | $45.00 | $225,000.00 |
DisclosureSEC source: 0000899243-18-000872 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,777 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 09, 2018 Filed Feb 15, 2018 20:27 UTC Amendment | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0000899243-18-004341 · doc4a.xml · derivative · entry 3 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,850 Underlying: Common Stock · 5,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2017, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| January 09, 2018 Filed Feb 15, 2018 20:27 UTC Amendment | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 5,000 | $45.00 | $225,000.00 |
DisclosureSEC source: 0000899243-18-004341 · doc4a.xml · nonDerivative · entry 2 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,777 F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 09, 2018 Filed Feb 15, 2018 20:27 UTC Amendment | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 5,000 | $12.25 | $61,250.00 |
DisclosureSEC source: 0000899243-18-004341 · doc4a.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 20:06 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 1,100 | $43.38 | $47,715.03 |
DisclosureSEC source: 0000899243-18-000380 · doc4.xml · nonDerivative · entry 2 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,777 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $43.20 to $43.60 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 20:06 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 3,900 | $42.76 | $166,750.74 |
DisclosureSEC source: 0000899243-18-000380 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,877 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $42.20 to $43.15 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2018 Filed Apr 17, 2019 20:25 UTC Amendment | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0000899243-19-010836 · doc4a.xml · derivative · entry 4 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,850 Underlying: Common Stock · 5,000 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2017, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| January 02, 2018 Filed Apr 17, 2019 20:25 UTC Amendment | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 1,100 | $43.38 | $47,715.03 |
DisclosureSEC source: 0000899243-19-010836 · doc4a.xml · nonDerivative · entry 3 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,777 F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Represents the weighted average sale price of the shares sold ranging from $43.20 to $43.60 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2018 Filed Apr 17, 2019 20:25 UTC Amendment | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 3,900 | $42.76 | $166,750.74 |
DisclosureSEC source: 0000899243-19-010836 · doc4a.xml · nonDerivative · entry 2 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,877 F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $42.20 to $43.15 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2018 Filed Apr 17, 2019 20:25 UTC Amendment | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 5,000 | $12.25 | $61,250.00 |
DisclosureSEC source: 0000899243-19-010836 · doc4a.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · shares: These shares were omitted from the Reporting Person's original Form 4, and also were omitted from the subsequent Form 4s filed by the Reporting Person through the date of this amendment Read SEC document |
| October 31, 2017 Filed Nov 3, 2017 19:45 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantCommon Stock | 1,232 | $11.56 | $14,241.92 |
DisclosureSEC source: 0000899243-17-025395 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,777 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 17:15 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 10,000 | $30.00 | $300,000.00 |
DisclosureSEC source: 0000899243-17-019942 · doc4.xml · nonDerivative · entry 2 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,545 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 17:15 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 5,000 | $25.00 | $125,000.00 |
DisclosureSEC source: 0000899243-17-019942 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,545 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 17:11 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 4,333 | $15.02 | $65,060.00 |
DisclosureSEC source: 0000899243-17-019194 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,545 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $15.00 to $15.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 16:05 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0000899243-17-018752 · doc4.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-07-19 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in two annual installments after the date of grant. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| April 28, 2017 Filed May 16, 2017 13:49 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantCommon Stock | 978 | $11.09 | $10,848.47 |
DisclosureSEC source: 0000899243-17-013323 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,878 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 17:30 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 5,102 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0000899243-17-008656 · doc4.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,204 Underlying: Common Stock · 5,102 shares Expires 2025-06-03 F1 · balance_after: On June 4, 2015, the Reporting Person was granted an option to purchase 20,408 shares of Common Stock under the issuer's 2012 Equity Incentive Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the issuer's securities. On March 23, 2017, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 5,102 of the shares underlying such option. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 20:37 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 667 | $15.00 | $10,005.00 |
DisclosureSEC source: 0000899243-17-008435 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,900 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 17:41 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 59,850 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0000899243-17-001671 · doc4.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,850 Underlying: Common Stock · 59,850 shares Expires 2027-01-17 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2017, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| November 01, 2016 Filed Nov 2, 2016 17:41 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 5,102 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0000899243-16-032643 · doc4.xml · derivative · entry 2 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,102 Underlying: Common Stock · 5,102 shares Expires 2025-06-03 F2 · balance_after: On June 4, 2015, the Reporting Person was granted an option to purchase 20,408 shares of Common Stock under the issuer's 2012 Equity Incentive Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the issuer's securities. On November 1, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 5,102 of the shares underlying such option. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 17:41 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantCommon Stock | 1,519 | $10.03 | $15,235.57 |
DisclosureSEC source: 0000899243-16-032643 · doc4.xml · nonDerivative · entry 1 Bauer Jake · CIK 0001654909 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,567 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.